Patents by Inventor Selma Sapmaz

Selma Sapmaz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds useful for inhibiting ROR?t
    Patent number: 11008336
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof, formula (A).
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 18, 2021
    Assignee: Eli Lilly and Company
    Inventors: Christian Alexander Clarke, Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Rudyk, Selma Sapmaz, Ryan Edward Stites, Grant Mathews Vaught
  • Compounds useful for inhibiting ROR-gamma-t
    Patent number: 10603320
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof. Formula (I).
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: March 31, 2020
    Assignee: Eli Lilly and Company
    Inventors: Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Catherine Eugenie Rudyk, Selma Sapmaz, Ryan Edward Stites
  • COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T
    Publication number: 20200048279
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof, formula (A).
    Type: Application
    Filed: February 27, 2018
    Publication date: February 13, 2020
    Inventors: Christian Alexander Clarke, Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Rudyk, Selma Sapmaz, Ryan Edward Stites, Grant Mathews Vaught
  • COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T
    Publication number: 20200009139
    Abstract: The present invention provides novel ROR gamma-t inhibitors and pharmaceutical compositions thereof. Formula (I).
    Type: Application
    Filed: February 27, 2018
    Publication date: January 9, 2020
    Inventors: Charles Willis Lugar, III, John Richard Morphy, Timothy Ivo Richardson, Helene Catherine Eugenie Rudyk, Selma Sapmaz, Ryan Edward Stites
  • 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds
    Patent number: 8778946
    Abstract: The invention provides certain 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds, particularly compounds of formula I and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat Parkinsons disease Formula (I).
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: July 15, 2014
    Assignee: Eli Lilly and Company
    Inventors: Carlos Lamas-Peteira, Simon James Richards, Selma Sapmaz, Magnus Wilhelm Walter
  • 6-arylalkylamino-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 8680091
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: March 25, 2014
    Assignee: Eli Lilly and Company
    Inventors: Karen Briner, Manuel Javier Cases-Thomas, Marta Adeva Bartolome, Christopher Stanley Galka, Alicia Marcos Llorente, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, John Cunningham O'Toole, Richard Edmund Rathmell, Matthew Robert Reinhard, Selma Sapmaz, Andrew Caerwyn Williams
  • 3-SUBSTITUTED-6-(PYRIDINYLMETHOXY)-PYRROLOPYRIDINE COMPOUNDS
    Publication number: 20130225602
    Abstract: The invention provides certain 3-substituted-6-(pyridinylmethoxy)-pyrrolopyridine compounds, particularly compounds of formula I and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat Parkinsons disease Formula (I).
    Type: Application
    Filed: November 17, 2011
    Publication date: August 29, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventors: Carlos Lamas-Peteira, Simon James Richards, Selma Sapmaz, Magnus Wilhelm Walter
  • 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HTreceptor agonists
    Patent number: 8420631
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is —C?C—R10, —CH?CR11R11?, or —(C0-C8)alkyl-Ar2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.
    Type: Grant
    Filed: September 1, 2006
    Date of Patent: April 16, 2013
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Karin Briner, Anne Marie Camp, Manuel Javier Cases-Thomas, Richard Charles Hoying, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, Natalia Pokrovskaia, Richard Edmund Rathmell, Roger Ryan Rothhaar, Selma Sapmaz, Andrew Caerwyn Williams
  • 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
    Publication number: 20110269745
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.
    Type: Application
    Filed: June 9, 2011
    Publication date: November 3, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Karin BRINER, Marta ADEVA BARTOLOME, Manuel Javier CASES-THOMAS, Christopher Stanley GALKA, Alicia MARCOS LLORENTE, Maria Angeles MARTINEZ-GRAU, Michael Philip MAZANETZ, John Cunningham O'Toole, Richard Edmund RATHMELL, Matthew Robert REINHARD, Selma SAPMAZ, Andrew Caerwyn WILLIAMS
  • 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists
    Publication number: 20080269196
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.
    Type: Application
    Filed: September 1, 2006
    Publication date: October 30, 2008
    Inventors: Karin Briner, Maria Adeva Bartolome, Manuel Javier Cases-Thomas, Christopher Stanley Galka, Alicia Marcos Llorente, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, John Cunningham O' Toole, Richard Edmund Rathmell, Matthew Robert Reinhard, Selma Sapmaz, Andrew Caerwyn Williams
  • 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists
    Publication number: 20080207897
    Abstract: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is —C?C—R10, —CH?CR11R11?, or —(C0-C8)alkyl-Ar2 optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification.
    Type: Application
    Filed: September 1, 2006
    Publication date: August 28, 2008
    Inventors: John Gordon Allen, Karin Briner, Anne Marie Camp, Manuel Javier Cases-Thomas, Richard Charles Hoying, Maria Angeles Martinez-Grau, Michael Philip Mazanetz, Natalia Pokrovskaia, Richard Edmund Rathmell, Roger Ryan Rothhaar, Selma Sapmaz, Andrew Caerwyn Williams